AngioDynamics, Inc.
NASDAQ:ANGOMedical - Instruments & Supplies
+$0.20 today
- Market cap
- $476.06M
- Beta
- 0.36
- P/E (TTM)
- -15.8
- EPS (TTM)
- -$0.75
Volume 0.32M
Average 0.40M
ANGO Pre-Tax Margin
Income before tax as a percentage of revenue.
AngioDynamics, Inc.NASDAQ: ANGO
Pre-Tax Margin · Q3 FY2026 · quarter ended Feb 2026
Pre-tax margin narrows to -10.3%
Pre-tax margin was -10.3% in Q3 FY2026, down 4.2 pp from a year earlier. On a trailing-twelve-month basis it was -10.0%, up 4.8 pp year over year. Over 3 fiscal years it narrowed by 2.2 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -11.6%
- Year-over-year change
- +51.4pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-31 | -11.6% | +51.4pp |
| FY2024 | 2024-05-31 | -63.1% | -47.0pp |
| FY2023 | 2023-05-31 | -16.1% | -6.6pp |
| FY2022 | 2022-05-31 | -9.5% | +2.9pp |
| FY2021 | 2021-05-31 | -12.4% | — |
Pre-Tax Margin vs competitors
How ANGO compares with its peers on the latest reported figures
- ANGO's LTM Feb 2026 pre-tax margin of -10.0% is the 7th highest of the 9 companies compared; the peer median is 11.5%.
- Its year-over-year change of +4.8 pp is the 2nd highest of 9, against a peer median of +0.6 pp.
- Over three fiscal years its change of -2.2 pp compares with a peer median of +6.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 31.5% | +5.7 pp | +13.1 pp | |
| LTM Jun 2026 | 18.4% | +2.2 pp | +7.9 pp | |
| LTM Jun 2026 | 13.5% | +0.0 pp | +14.2 pp | |
| LTM Sep 2026 | 13.1% | +2.8 pp | +4.1 pp | |
| LTM Sep 2026 | 9.8% | +1.2 pp | +0.7 pp | |
| LTM Mar 2026 | 6.0% | -5.1 pp | +12.0 pp | |
| LTM Feb 2026 | -10.0% | +4.8 pp | -2.2 pp | |
| LTM Jun 2026 | -15.8% | -23.9 pp | -14.7 pp | |
| LTM Mar 2026 | -32.6% | -29.9 pp | -48.2 pp | |
| Peer median (excluding ANGO) | 11.5% | +0.6 pp | +6.0 pp | |
Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Revenue | 291.01M | 316.22M | 338.75M | 303.91M | 292.5M |
| Cost of Revenue | 134.22M | 150.49M | 164.51M | 149.22M | 134.79M |
| Gross Profit | 156.79M | 165.73M | 174.25M | 154.7M | 157.71M |
| Gross Margin | 53.9% | 52.4% | 51.4% | 50.9% | 53.9% |
| Research & Development | 36.39M | 30.74M | 29.88M | 31.51M | 26.22M |
| Selling, General & Admin | 117.22M | 133.75M | 144.25M | 143.98M | 145.23M |
| Operating Expenses | 192.07M | 194.2M | 225.43M | 347.13M | 197.66M |
| Depreciation & Amortization | 25.92M | 29.35M | 30.87M | 27.71M | 25.8M |
| EBITDA | (9.28M) | 11.13M | 12.19M | (6.13M) | 1.74M |
| EBITDA Margin | -3.2% | 3.5% | 3.6% | -2.0% | 0.6% |
| Operating Income | (35.28M) | (28.47M) | (51.18M) | (192.44M) | (39.95M) |
| Operating Margin | -12.1% | -9.0% | -15.1% | -63.3% | -13.7% |
| Interest Income | 0 | 0 | 0 | 1.61M | 978K |
| Interest Expense | 861K | 688K | 2.7M | 0 | 0 |
| Other Income / Expenses | (769K) | (1.48M) | (3.26M) | 797K | 5.92M |
| Income Before Tax | (36.05M) | (29.95M) | (54.44M) | (191.64M) | (34.03M) |
| Pre-Tax Margin | -12.4% | -9.5% | -16.1% | -63.1% | -11.6% |
| Income Tax Expense | (4.5M) | (3.4M) | (2M) | (7.29M) | (39K) |
| Net Income | (31.55M) | (26.55M) | (52.44M) | (184.35M) | (33.99M) |
| Net Margin | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% |
| EPS (Basic) | (0.82) | (0.68) | (1.33) | (4.59) | (0.83) |
| EPS (Diluted) | (0.82) | (0.68) | (1.33) | (4.59) | (0.83) |
| Weighted Avg Shares | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M |
| Weighted Avg Shares (Diluted) | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M |
AngioDynamics, Inc.
NASDAQ:ANGO
Intrinsic Alpha fair value
Locked
Current Price
$11.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.